MetaCap

Autolus Therapeutics (AUTL) vs SAB Biotherapeutics (SABS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Autolus Therapeutics (AUTL) has outperformed SAB Biotherapeutics (SABS) over the past year, losing 26.2% versus a loss of 28.9%. Over five years, AUTL leads with a -85.5% price change compared with -97.3% for SABS. SAB Biotherapeutics is the larger company by market cap ($253.1 million vs $241.7 million), about 1.0 times the size, while Autolus Therapeutics is growing revenue faster (+644.9% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AUTL-26.24%SABS-28.86%
+114%+35%-44%
Nov 21, 20251 yearNov 20, 2026
AUTL-85.41%SABS-97.45%
+21%-42%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AUTL versus SABS key metrics
MetricAUTLSABS
Share price$0.9073$2.81
Market cap$241.65M$253.15M
1-day change-7.38%-3.44%
YTD return-54.41%-24.87%
1-year return-26.24%-28.86%
5-year return-85.51%-97.32%
EPS (TTM)$-0.96$-1.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$75.39M$0
Revenue growth (YoY)+644.94%-100.00%
Net income (latest FY)$-287.53M$13.27M
Gross margin-27.83%—
Operating margin-358.87%—
Net margin-381.40%—
52-week high$2.58$5.15
52-week low$0.896$2.44
Distance from 52-week high-64.83%-45.44%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+821.42%+314.23%
Average volume2.07M633.60K
Shares outstanding266.34M90.09M
Employees75286
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Autolus Therapeutics grew revenue faster in its latest fiscal year (+644.94% vs -100.00%).

About Autolus Therapeutics

AUTL stock →

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees

About SAB Biotherapeutics

SABS stock →

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees

AUTL vs SABS FAQ

Which is bigger, Autolus Therapeutics or SAB Biotherapeutics?

SAB Biotherapeutics (SABS) is larger, with a market capitalization of $253.15M compared with $241.65M for Autolus Therapeutics (AUTL).

Which stock has performed better over the past year, AUTL or SABS?

AUTL returned -26.24% over the past 12 months, compared with -28.86% for SABS (price return, excluding dividends). Past performance does not predict future results.

Are Autolus Therapeutics and SAB Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons